Related Experiment Video
Updated: Jul 6, 2026

07:40
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
Autoimmune retinopathy: a review and summary
John R Heckenlively1, Henry A Ferreyra
1Kellogg Eye Center, University of Michigan, Ann Arbor, MI 48105, USA. jrheck@umich.edu
Seminars in Immunopathology
|April 15, 2008
Summary
Autoimmune retinopathy (AIR) encompasses several forms, including cancer-associated retinopathy (CAR) and melanoma-associated retinopathy (MAR). Patients experience sudden vision loss and abnormal ERGs due to panretinal degeneration.
Area of Science:
- Ophthalmology
- Immunology
- Retinal Diseases
Background:
- Autoimmune retinopathy (AIR) comprises three primary forms: cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR), and nonneoplastic autoimmune retinopathy (npAIR).
- AIR can also arise secondary to other ocular conditions like retinitis pigmentosa, ocular trauma, birdshot retinopathy, acute zonal occult outer retinopathy (AZOOR), and multiple evanescent white dot syndrome (MEWDS).
Observation:
- Despite diverse origins, various forms of AIR share common clinical manifestations.
- A notable characteristic is the absence of a uniform set of anti-retinal antibodies across all patients.
- Patients often exhibit a broad spectrum of anti-retinal antibody activity, frequently identifying three to six distinct antibodies via immunoblots.
Findings:
- Clinical presentation typically includes sudden-onset photopsia (flashing lights) and rapid visual deterioration.
- Electroretinograms (ERGs) are consistently abnormal in affected individuals.
- Pathological findings often reveal panretinal degeneration, typically without pigment deposits.
Implications:
- Understanding the commonalities and variations in AIR is crucial for accurate diagnosis and management.
- Further research into the specific anti-retinal antibodies involved may elucidate pathogenic mechanisms.
- Improved diagnostic markers and targeted therapies are needed for patients with autoimmune retinopathy.

